写好临床医学研究论文结构式摘要中方法、结果部分的要点.pdf
写好临床医学研究论文结构式摘要中方法、结果部分的要点.pdf
中国癌症杂志 2009年第19卷第1期 47
[4]
[5]
(6]
Hidalgo M,Rowinsky EK.The rapamycin—sensitive signal
transduction pathway as a target for cancer therapy[J].
Oncogene.2000.19:6680—6686.
周小娟,郑棋,赵小丽,等.榄香烯联合 苯氧胺对乳腺
癌MCF一7细胞株的抑制效应 [J].西安交通大学学报(医
学版),2007.28(1):74—77.
Stem M.Herrmann R.Ove~iew of monoclonal antibodies in
cancer therapy.Present and promise l J J.Crit Rev in Oncol/
Hemato1.2005.54:l l一29.
[7]
[8]
[9]
Guertin DA.Sabatini DM.An expanding role for mT0R in
cancer l J j.Tremls Mol Med,2005,I1(8):353—361.
Bjomsti MA,Houghton PJ.The TOR pathway:A target for
cancer therapy l J J.Nat Rev Cancer,2004,4(5):335—348.
Gera JF,Melinghof IK,Shi Y,et a1.AKT activity determines
sensitivitv to mammalian target of mpamv in(mT0R)inhibitors
by regulating cyclin DI and c—myc expression l J].J Biol
Chem 2Oo4,279f4):2737—2746.
(收稿 日期:2008—09—17 修回13期:2008—12—17)
; 写好临床医学研究论文结构式摘要中方法、 ;
● ●
● ●
; 结果部分的要点
: 1 在结构式摘要方法部分中应描述的内容 病例收集时 :
: 间与分组、例数、性别、年龄、平均年龄 (范围)、肿瘤
; 类型、分期、外科适应证与术式、内科化疗入组条件、化
: 疗剂量、用药方法。
: 2 在结构式摘要结果部分中应描述的内容 近期疗效
; (cR、PR)、生存率、中位随访时间、中位住院时间、
: 死亡例数与原因、毒副作用情况 (%)、并发症。
: 论文正文中更应包括这些内容。 :
: 本刊编据-l-J~.部 : ● I 讯 H ●
● ● ● ● ● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ● ● ● ● ●
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ● ● ● ● ● ● ● ● ● ● ●
...